Detail akcie Moderna Rg online

Business Summary: Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Financial Summary: BRIEF: For the six months ended 30 June 2025, Moderna Inc revenues decreased 39% to $250M. Net loss decreased 27% to $1.8B. Revenues reflect United States segment decrease of 55% to $119M, Rest of the World segment decrease of 9% to $81M. Lower net loss reflects Research and development decrease of 35% to $1.41B (expense), General and administrative decrease of 23% to $361M (expense).